Nuformix Share Discussion Threads

[for fx sake] 03/8/2021 14:11

It will have to come off suicide watch first.

[sentiment riles] 03/8/2021 13:49

Very tempted to put NFX on takeover watch

[sentiment riles] 02/8/2021 14:11

Check back in at 4.8p

Hopefully not too far away

[sentiment riles] 02/8/2021 14:10

And lets be honest here, Brindley will be focussed on leaving at a good time ie not carrying bad work into a new job imo. bad bad look for her personally if did

"SR sees glory "

[sentiment riles] 02/8/2021 14:02

Excellent company. The lads sure got their value from CEO rns

Reckon they are buying the value for next RNS?

Target

7.5p (obviously not in one week)

Like Dr Alastair Riddell

Pity there isnt more like him in small stocks. A rare gem

Would like him in the CEO seat, but he probably will be considering 30 years of blue-chip, credible contacts, to bring in the 'big deal' hitman/woman

[sentiment riles] 02/8/2021 13:28

Seems to be a big market in here today with no news

Looking good for some it seems

[bigberty99] 02/8/2021 13:27

Valli is pumping his dog again

[spurs90] 01/8/2021 20:28

Utilising a technology known as cocrystallisation, Nuformix re-engineers a drug’s crystalline form by adding a molecule that improves it in a variety of ways – how well it can be absorbed by the body, for example.

Drug repurposing is a well-known strategy for enhancing the therapeutic and commercial value of marketed drugs:
• Greater probability of success compared to developing new drugs, due to the existing data, particularly safety, already generated on the marketed drug.
• Existence of data may also result in lower overall development costs and shorter development timelines.
• Commercial potential of these drugs may be enhanced by differentiation by way of formulation, route of administration or dose and gaining patent protection.
We aim to use our expertise in solid form science to discover and file patent applications on new solid forms to facilitate development of alternative formulations and delivery methods to repurpose marketed drugs into differentiated products for new indications.

Nuformix looks for three things in candidates suitable for their approach to reprofiling.
“Is the drug safe, does it have a problem our tech can improve and is there an underlying therapeutically innovative pharmacology with some level of validation in an area of unmet medical need.”
For example, using cocrystal technology can change key drug properties, such as solubility or dissolution rate, without changing the chemistry inside.
That means a drug can dissolve faster and to a greater extent so more of the drug gets into the patient, though solubility is just one of many problems an existing drug might face.
“Many properties hold drugs back from doing other things, but in certain cases we have an opportunity to change that.
“When we discover new drug cocrystals, we can patent these new substances and leverage their improved properties in new and unique products.”
“Every drug cocrystal we discover, we breathe a new 20-year lifespan into products enabled by that substance.”

Drug reprofiling
Switching disease use is called drug reprofiling and means rather than starting from scratch when designing a new therapy, you take a treatment for disease A and reprofile it to treat disease B.
Because known drugs have usually been approved previously and their underlying chemistry is not changing, safety issues have been addressed, removing a major hurdle in drug development.
That leaves Nuformix just to prove that the new application passes muster against existing standard of care treatments.
“We take our cocrystal-based products through development to proof-of-concept stage before seeking to out-license to a marketing partner,”

There has been a spate of preclinical deals, not least by the UK’s C4X Discovery, which has landed two separate partnerships – one with Indivior the other with Sanofi – worth a combined £580mln in upfront, milestone and royalty payments. More relevant and in the area of fibrosis (IPF), AIM-listed Redx Pharma inked a licensing agreement with AstraZeneca worth a headline US$377mln and upfront milestone; and another preclinical licensing agreement with Abbvie and Morphic Therapeutics was also done with an undisclosed headline value, again with upfront milestones.

In NXP002, Nuformix has eschewed traditional drug development by creating a new form of the original drug, tranilast, which has a long history of safe use as an oral drug for allergies in Asia but with evidence that supports its potential in fibrosis, including IPF.
Nuformix has generated its own IP, repurposing an existing drug and giving it a potential new lease of life with significant commercial potential.
NXP002 is differentiated because it's a new form of tranilast and it will be formulated for delivery direct to the lungs by inhalation, a new route of administration for this drug.
There are two reasons why this change in route of administration is important.
The first is practical as it provides a targeted treatment with hopefully fewer side-effects.

The second is that by discovering novel forms of tranilast, Nuformix is able to generate IP and get patent protection from generics.
IPF itself is an area of high unmet medical need and an ‘orphan’ disease. It’s a severe and progressive disease that affects the lungs, where dust, smoke, gastric reflux acid, genetic predisposition or infection leads to scarring known as fibrosis.
The prognosis is as bleak as some aggressive forms of cancer with an average survival time of three to five years.
While there are treatments, they tend only to be partially effective and have significant side-effects that cause some patients to stop treatment.
Because of the rarity of the disease, any new drugs that show signs of potential efficacy are likely to receive orphan drug designation.
This regulatory classification expedites the clinical trial process, reduces costs and extends the exclusivity period of the end product.
Taking the re-purposing route with Tranilast, rather than developing and testing a totally new molecule, compound or cell therapy, may also help shorten the timeline to market.
For example, a lot is already known about the safety and the way a drug such as Tranilast interacts with the body.
So, in this regard, there is also a greater probability of success, while the development costs are likely also to be lower than they would be with an unknown new therapy.

[for fx sake] 29/7/2021 15:01

I don't think they'd be able to recruit, as things stand. Maybe if Oxilio comes off or the data is positive, then they will perhaps have something to offer

[hollywood6] 29/7/2021 12:42

Agreed, only time will tell. We don't know Anne well enough to k ow what she is thinking. We would obviously like to assume she is ethical and has some moral obligations but we don't know

[hollywood6] 29/7/2021 12:40

Is the company now looking to recruit a replacement for Anne? I have not had a response to my email. Normal arrangements would be to announce they will be looking to recruit following her resignation.At least we are fully funded for initial plans and NXP002 data. We desperately need positive news here. It's going to all hinge on it. Anyone know if there has been any lab delays?

[sentiment riles] 27/7/2021 15:45

Good point

[for fx sake] 27/7/2021 15:40

Dumping a role when the client is already fragile and likely to end up in a worse state never looks good on a CV, even if the job you're heading too is amongst friends.She will know that. She may well have it mapped out such that things start to come together before she actually goes. If she leaves it in a good state then it won't look so mercenary. Only time will tell.

[sentiment riles] 27/7/2021 15:17

Staying on 6 months is a good thing. The next company wouldn't want her bringing any baggage. so looks like there will not be any

[dailylarma] 27/7/2021 14:57

Sell up now and move into BIDSGet some of your money back

[dennisbergkamp] 27/7/2021 14:35

Maybe more a decision based on her inability to make anything of this company... As soon as his cover was blown (Wenger leaving after fronting all the stick for his shoddy work) Gazidis walked as he knew he'd be found out...

Think she did an interview on Proactive (or similar) recently where she couldn't recall a thing without staring at her fact sheet the whole way through... She was literally reading off a sheet the whole way through

Doesn't detract from the shambles... One of my less clever plays... Love to be proven wrong though...

D

[parsons4] 27/7/2021 14:08

Just bought in again, I also don't think she would have stayed on for 6 months if something was untoward !!

[senseman] 23/7/2021 13:20

Brindley leaving in this manner after 7 months is utter disgrace - chair and SHs seriously peed off, as is senseman. no CEO should be a 'better offer' girl or guy until at least 3yrs at company. completely unethical. i hope her new company goes t*ts up and no one trusts her ever again - i wouldn't

[sentiment riles] 23/7/2021 13:00

Bored of only shorting. So i decided to find the small company buy for 2021 no matter what the market environment

NFX is it

[for fx sake] 23/7/2021 10:01

Read the Chairman's letter. He seems confident that money is not an issue

[for fx sake] 23/7/2021 09:35

I can't help feeling disappointment at her decision to leave, on the face of it. I mean, she came into a role where lots of execs had already left and the share price had been trashed as a result. She must have been fully aware that shareholders were sensitive to sudden departures and that doing the same (especially at a critical time and for personal gain) would be a huge blow.That's if things are as they seem though. It doesn't really make sense to me to leave when things are stabilising and possibly looking up. If friends had made the offer surely they could wait a bit longer. When things don't make sense then you have to try and look at what does.When Anne came in, she had two ex-colleagues here, Blackwell and Keegan. It looked like a stable team with a good track record was being built. Then, out of the blue, Blackwell leaves. I do wonder if Anne had any idea that that was going to happen. If not, things have suddenly changed. Next to go is Keegan along with the CSO and ex-founder Jo Holland. Now Anne is going too.What is the probability that these events are not somehow linked? It could be down to chaos or it could be something else. Perhaps, the company is now in the final stages of being packaged up for a buy out. Maybe, these people are moving on because the job is almost done and it is part of the plan (although Anne's departure did not seem planned after reading the Chairman's letter). Holland and Gooding still hold all their shares. Time will tell

[amaretto1] 23/7/2021 09:17

In 6 months .. will they have any money left ? I'm thinking they will not, and the consequences is NFX could be wound up !!